MX2023002589A - Derivados de fumagilol y polimorfos de los mismos. - Google Patents

Derivados de fumagilol y polimorfos de los mismos.

Info

Publication number
MX2023002589A
MX2023002589A MX2023002589A MX2023002589A MX2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A
Authority
MX
Mexico
Prior art keywords
polymorphs
fumagillol derivatives
fumagill
aminocyclohexyl
trans
Prior art date
Application number
MX2023002589A
Other languages
English (en)
Inventor
John S Petersen
Original Assignee
Syndevrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndevrx Inc filed Critical Syndevrx Inc
Publication of MX2023002589A publication Critical patent/MX2023002589A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C07C309/26—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a sales y polimorfos de carbamatos de aminoalquilfumagilol (por ejemplo, sal de ácido bencenosulfónico de N-(trans-4-aminociclohexil)carbamato de fumagil-6-ilo y sal de ácido hidroxinaftoico de N-(trans-4-aminociclohexil)carbamato de fumagil-6-ilo). Los polimorfos se caracterizan por difracción de polvo de rayos X, calorimetría de exploración diferencial y análisis termogravimétrico, entre otros métodos. Los polimorfos y sales pueden usarse como intermediarios en la producción de derivados de fumagilol (por ejemplo, derivados de fumagilol conjugados con polímero) así como agentes terapéuticos para el tratamiento de varias enfermedades y condiciones tales como cáncer.
MX2023002589A 2015-12-10 2018-06-06 Derivados de fumagilol y polimorfos de los mismos. MX2023002589A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265675P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
MX2023002589A true MX2023002589A (es) 2023-03-22

Family

ID=57589276

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018006904A MX2018006904A (es) 2015-12-10 2016-12-09 Derivados de fumagilol y polimorfos de los mismos.
MX2023002589A MX2023002589A (es) 2015-12-10 2018-06-06 Derivados de fumagilol y polimorfos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018006904A MX2018006904A (es) 2015-12-10 2016-12-09 Derivados de fumagilol y polimorfos de los mismos.

Country Status (12)

Country Link
US (2) US9969722B2 (es)
EP (1) EP3386956B1 (es)
JP (2) JP7553224B2 (es)
KR (1) KR20180093995A (es)
CN (1) CN108290853B (es)
AU (1) AU2016366306B2 (es)
CA (1) CA3005450A1 (es)
DK (1) DK3386956T3 (es)
ES (1) ES2893749T3 (es)
HK (1) HK1258254A1 (es)
MX (2) MX2018006904A (es)
WO (1) WO2017100553A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2853204T3 (es) 2010-05-25 2021-09-15 Syndevrx Inc Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos
ES2902082T3 (es) 2013-04-10 2022-03-24 Syndevrx Inc Inhibidores de MetAP2 Fumagillol conjugados a polímero o modificados para mejorar o restaurar la sensibilidad a la insulina
MX2018008321A (es) 2016-01-11 2018-09-21 Syndevrx Inc Tratamiento de tumores ocasionados por disfuncion metabolica.
CA3117666A1 (en) 2018-10-26 2020-04-30 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
WO2024040009A2 (en) * 2022-08-17 2024-02-22 Primetime Life Sciences, Llc Inhibitors of methionine aminopeptidase-2 and methods of preparation and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US4997878A (en) 1988-12-29 1991-03-05 Exxon Research And Engineering Company Hydrophobically associating polymers containing dimethyl acrylamide functionality
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US20020076442A1 (en) 1997-09-02 2002-06-20 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
ES2224465T3 (es) 1997-10-31 2005-03-01 Children's Medical Center Corporation Metodo para regular el tamaño y el crecimiento del tejido normal vascularizado.
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
CN1250293C (zh) 1998-05-22 2006-04-12 第一制药株式会社 药物复合物
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
AU765409B2 (en) 1998-10-30 2003-09-18 Daiichi Pharmaceutical Co., Ltd. DDS compounds and method for assaying the same
EP1222217B1 (en) 1999-09-08 2005-06-15 Polytherics Limited Uniform molecular weight polymers
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US20070161570A1 (en) 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1436286B1 (en) 2001-09-27 2009-08-19 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
US20060099660A1 (en) 2002-02-15 2006-05-11 Synovo Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
JP4514455B2 (ja) 2002-04-11 2010-07-28 チルドレンズ メディカル センター コーポレーション Ｔｎｐ−４７０ポリマー複合体及びその使用
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US20040116348A1 (en) 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US20040228831A1 (en) 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
US7700280B2 (en) 2003-12-31 2010-04-20 The Penn State Research Foundation Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US7214664B2 (en) 2004-12-03 2007-05-08 The Curators Of The University Of Missouri Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
US20080248030A1 (en) 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2006124711A1 (en) 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
AU2008268262C1 (en) 2007-06-26 2015-02-19 Children's Medical Center Corporation MetAP-2 inhibitor polymersomes for therapeutic administration
WO2009036108A1 (en) 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
EA020251B1 (ru) 2007-11-28 2014-09-30 Мерсана Терапьютикс, Инк. Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
EP2229387A1 (en) 2007-12-04 2010-09-22 Cadila Healthcare Limited Process for preparing chemically and chirally pure solifenacin base and its salts
US8124603B2 (en) 2008-01-22 2012-02-28 Thar Pharmaceuticals In vivo studies of crystalline forms of meloxicam
EP2307032A4 (en) 2008-05-22 2014-08-20 Univ Ramot NOVEL POLYMER CONJUGATES HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS-TARGETING FRACTION AND USES THEREOF FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
TWI373345B (en) 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital INHIBITION OF NOTCH FOR THE TREATMENT AND PREVENTION OF OBESITY AND METABOLIC SYNDROME
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
ES2853204T3 (es) 2010-05-25 2021-09-15 Syndevrx Inc Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US20110294952A1 (en) 2010-05-25 2011-12-01 SynDevRX Optimized Drug Conjugates
EP2638023B1 (en) 2010-11-09 2016-09-07 Zafgen, Inc. Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012122264A1 (en) 2011-03-08 2012-09-13 Zafgen Corporation Oxaspiro [2.5] octane derivatives and analogs
EP2850079B1 (en) * 2012-05-09 2018-05-02 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
ES2902082T3 (es) 2013-04-10 2022-03-24 Syndevrx Inc Inhibidores de MetAP2 Fumagillol conjugados a polímero o modificados para mejorar o restaurar la sensibilidad a la insulina
MX2018008321A (es) 2016-01-11 2018-09-21 Syndevrx Inc Tratamiento de tumores ocasionados por disfuncion metabolica.

Also Published As

Publication number Publication date
CA3005450A1 (en) 2017-06-15
US20180291010A1 (en) 2018-10-11
DK3386956T3 (da) 2021-10-11
EP3386956A1 (en) 2018-10-17
US9969722B2 (en) 2018-05-15
AU2016366306B2 (en) 2021-02-25
AU2016366306A1 (en) 2018-05-31
CN108290853A (zh) 2018-07-17
ES2893749T3 (es) 2022-02-10
HK1258254A1 (zh) 2019-11-08
US10287277B2 (en) 2019-05-14
MX2018006904A (es) 2018-08-24
CN108290853B (zh) 2022-05-31
WO2017100553A1 (en) 2017-06-15
EP3386956B1 (en) 2021-07-14
KR20180093995A (ko) 2018-08-22
US20170166556A1 (en) 2017-06-15
JP2019501898A (ja) 2019-01-24
JP2024103495A (ja) 2024-08-01
JP7553224B2 (ja) 2024-09-18

Similar Documents

Publication Publication Date Title
MX2023002589A (es) Derivados de fumagilol y polimorfos de los mismos.
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
CY1119731T1 (el) Διαδικασια για την παρασκευη παραγωγων χολικου οξεος
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
MX2015018048A (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
MX2021014128A (es) Polimorfos de selinexor.
WO2014152389A8 (en) Imaging agent for detection of diseased cells
EA201691629A1 (ru) Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
CY1121137T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν ανταγωνιστες ccr3
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
EA201592144A1 (ru) Производное фенола, способ его получения и его применение в медицине
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MY160785A (en) Manufacturing process for pyrimidine derivatives
EA201691141A1 (ru) Соединения против ccr6
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
EA201891023A1 (ru) Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
CL2020001589A1 (es) Proceso para la preparación de derivados de quinolina.
AU2018341781A8 (en) Fused ring derivative as A2A receptor inhibitor
CY1124838T1 (el) Αλας παραγωγου κεφαλοσπορινης, κρυσταλλικη, στερεη μορφη αυτου και μεθοδος παραγωγης αυτου